CBG and Anxiety: What the First Human Trial Found, and What Remains Open

For most of its research history, cannabigerol occupied a supporting role. It was studied as a precursor — the compound from which other cannabinoids develop during plant maturation — and examined primarily in cell cultures and animal models. Human trial data was essentially absent. That changed in 2024, when a team at Washington State University published the first double-blind, placebo-controlled crossover trial examining CBG's acute effects on anxiety, stress, and mood in healthy adults. The findings were specific enough to be scientifically interesting and limited enough to require careful reading.

This article examines what that trial found, what the mechanistic research suggests, and where the evidence currently stands. It does not offer clinical guidance. It offers an honest account of one significant study and the biological context that makes it worth understanding.

The Biological Pathways Under Investigation

CBG interacts with several receptor systems that researchers have identified as relevant to stress and anxiety regulation. Understanding these interactions provides biological plausibility for the human findings — though, as with all mechanistic research, plausibility is not the same as demonstrated effect. See our overview of how cannabinoids interact with the body for a broader introduction to these pathways.

The Endocannabinoid System

CBG binds to both CB1 and CB2 receptors, though with comparatively low affinity relative to THC. It does not produce intoxicating effects. Its endocannabinoid system interactions are thought to be modulatory rather than strongly agonistic — influencing system tone without the direct receptor activation that characterizes THC's psychoactive profile.

Alpha-2 Adrenoceptors

Preclinical research has identified CBG as a potent alpha-2 adrenoceptor agonist. These receptors are involved in the regulation of sympathetic nervous system activity and stress response — specifically in modulating the physiological arousal associated with acute stress. The relevance of this mechanism to human anxiety experience remains under investigation, but it represents one of the more pharmacologically specific findings in the CBG literature.

Serotonin Receptors

CBG has also demonstrated activity at the 5-HT1A serotonin receptor in laboratory models, though the nature of that interaction — whether agonist or antagonist — has been characterized differently across studies. The 5-HT1A receptor has been extensively studied in anxiety and mood research. How CBG's interaction with it translates to human experience is not yet established. See our article on the endocannabinoid system and stress response for additional context on these signaling pathways.

The 2024 Human Trial: Design and Findings

The Cuttler et al. (2024) trial, published in Scientific Reports, represents the current anchor of the human CBG research base. It is worth examining in some detail — both for what it found and for what its design permits us to conclude.

These are meaningful findings. A double-blind, placebo-controlled crossover design is the appropriate methodology for this kind of question, and the anxiety reductions were statistically significant at multiple time points rather than a single marginal result. The absence of impairment is also notable — it distinguishes CBG's profile clearly from THC and addresses a practical concern for anyone considering cannabinoid use in daily life.

The limitations are equally real and must be stated plainly. A sample of 34 healthy adults is modest. The absence of diagnosed anxiety disorders in the study population means the findings cannot be directly applied to clinical anxiety — the biological and experiential profile of a healthy adult under mild acute stress differs from that of someone managing generalized anxiety disorder or panic disorder. The effects were measured acutely, over a single session, which tells us nothing about sustained use, tolerance, or long-term safety. And a single trial, however well-designed, requires replication before its findings can be considered established.

The Verbal Memory Finding

The unexpected improvement in verbal word recall deserves specific attention, because it is the finding most likely to be misrepresented — in either direction. Some writers will treat it as evidence that CBG enhances cognition. Others will dismiss it as a statistical artifact. Neither response is appropriate given what the study actually provides.

What the study provides is a statistically significant difference in one cognitive measure, in one population, in one trial, that the researchers themselves described as surprising. The lead author triple-checked the result before publication and specifically recommended replication as the appropriate next step. That is the honest representation of this finding: it is real, it is interesting, and it is not yet understood. It warrants follow-up investigation. It does not yet warrant claims about CBG's cognitive effects. Our CBG monograph tracks the developing research on this finding as new data becomes available.

Survey Data: A Different Kind of Signal

Beyond controlled trials, self-reported survey data indicates that many individuals who use CBG products do so for stress or anxiety-related reasons, and a portion report subjective benefit. This data is worth acknowledging because it reflects real human experience at scale. It is not worth treating as clinical evidence, because it cannot establish causation, control for expectation effects, or distinguish CBG's contribution from that of other compounds in a product or other factors in a person's life.

Survey data sits outside the Charter's evidence hierarchy for research conclusions. It is noted here for completeness — as a signal that the human trial findings connect to something people are experiencing in practice — not as corroboration of efficacy.

What the Evidence Does and Does Not Show

The honest summary of where CBG anxiety research stands in 2026: one well-designed human trial produced statistically significant reductions in subjective anxiety and stress in healthy adults following a single 20 mg dose, with no impairment detected and an unexpected cognitive signal requiring further investigation. The mechanistic picture — alpha-2 adrenoceptor agonism, 5-HT1A activity, endocannabinoid modulation — provides biological plausibility for these findings without explaining them conclusively.

What the evidence does not show: efficacy in diagnosed anxiety disorders, reliable effects across doses or formulations, long-term safety, or predictable therapeutic outcomes. CBG is not approved for the treatment of any anxiety condition. The research is preliminary, the sample is small, and the field is young.

What the research does show is a clear and reproducible signal in an appropriately designed study, and a mechanistic profile that makes continued investigation scientifically warranted. That is a meaningful place to be for a compound that had essentially no human trial data three years ago. It is not a destination. It is a beginning.

Open Questions and the Research Ahead

The questions the Cuttler trial raises but does not answer are, in some respects, more interesting than the findings themselves. Does the anxiolytic signal persist across repeated doses, or does tolerance develop? Are the effects dose-dependent in a linear or biphasic way? Do individuals with diagnosed anxiety disorders respond differently than healthy adults? What is the mechanistic basis of the verbal memory finding, and does it replicate? Does full-spectrum CBG produce different effects than isolate?

These are tractable questions. They require more human trials — larger, longer, more varied in population and design. The 2024 trial established that human research on CBG is feasible, that effects are measurable, and that the compound warrants serious scientific attention. That foundation makes the next generation of studies possible in a way they were not before.